+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Somatostatin Analogs Market by Molecule Type, Application, Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Somatostatin Analogs Market by Molecule Type, Application, Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Sale

Somatostatin Analogs Market by Molecule Type, Application, Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337116
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The somatostatin analogs market is advancing with innovative therapeutics and delivery systems, addressing unmet needs across endocrine, metabolic, and neuroendocrine disorders. Senior decision-makers seek actionable insights to navigate evolving opportunities and challenges in this dynamic sector.

Market Snapshot: Somatostatin Analogs Market Growth and Trends

The Somatostatin Analogs Market grew from USD 7.49 billion in 2024 to USD 8.30 billion in 2025. It is expected to continue growing at a CAGR of 10.36%, reaching USD 13.54 billion by 2030.

Scope & Segmentation

  • Molecule Type: Lanreotide, Octreotide, Pasireotide
  • Therapeutic Application: Acromegaly, Cushing’s Disease, Neuroendocrine Tumors
  • Route of Administration: Intramuscular Injection, Subcutaneous Injection
  • End User: Clinics, Home Care Services, Hospitals
  • Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • Dosage Form: Cartridges, Prefilled Syringes
  • Geographic Coverage: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Company Analysis: Novartis AG, Ipsen S.A., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Accord Healthcare Ltd
  • Technology Advancements: Biodegradable polymer matrices, smart injection devices, biosimilar development, companion diagnostics, peptide engineering, nanocarrier systems

Key Takeaways for Decision-Makers

  • Somatostatin analogs address critical unmet clinical needs, particularly in endocrine disorders such as acromegaly and neuroendocrine tumors, with ongoing research expanding their application to additional metabolic and inflammatory indications.
  • Development of patient-centric drug delivery, including sustained-release formulations and autoinjector-compatible cartridges, is enhancing treatment adherence and broadening patient access, particularly in home care settings.
  • Strategic alliances and licensing agreements between biopharma and technology partners are reshaping competitive dynamics by combining advanced formulation science with digital patient monitoring and companion diagnostics.
  • The rise of biosimilars, combined with expiration of exclusive patents on leading analogs, is altering pricing structures and intensifying market competition among established producers and new entrants.
  • Distribution channels are diversifying, with hospital pharmacies maintaining primacy while online platforms become increasingly relevant for decentralized and home-based care models.
  • Targeted innovation in receptor subtype affinity and personalized dosing is aligning with precision medicine trends, driving differentiation and supporting real-world outcome improvement.

Tariff Impact: Navigating U.S. Tariff Changes in 2025

The 2025 U.S. tariff revisions have introduced higher duties on key precursors and active ingredients, significantly affecting global supply chains for somatostatin analogs. Manufacturers dependent on transpacific imports are confronting compressed margins and revisiting supplier portfolios. Many are shifting toward nearshore and domestic production to improve supply security and manage input costs. Distribution partners and hospital purchasing groups are re-negotiating pricing to balance cost pressures with patient affordability and reimbursement realities. Strategic investments in advanced production techniques, including continuous flow chemistry and localized manufacturing, are reinforcing resilience amid ongoing tariff-driven uncertainties.

Methodology & Data Sources

This report is based on a robust research framework, integrating primary interviews with clinical and industry experts and a wide range of secondary sources, such as peer-reviewed journals, regulatory filings, and proprietary industry databases. A structured data triangulation approach ensures accuracy, with qualitative insights systematically coded to highlight emerging challenges and opportunities.

Why This Report Matters

  • Enables data-driven decisions by mapping market drivers, technology advancements, and regulatory dynamics impacting somatostatin analog adoption.
  • Helps stakeholders anticipate competitive shifts and align product portfolios to emerging precision medicine requirements and distribution models.
  • Offers a comprehensive segmentation and regional analysis, supporting tailored strategies for global market entry, local adaptation, and risk mitigation.

Conclusion

The somatostatin analogs market is shaped by scientific advances, evolving regulations, and shifting global supply strategies. In-depth industry intelligence supports leaders in identifying growth opportunities, optimizing product pipelines, and delivering improved patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Somatostatin Analogs Market, by Molecule Type
8.1. Introduction
8.2. Lanreotide
8.3. Octreotide
8.4. Pasireotide
9. Somatostatin Analogs Market, by Application
9.1. Introduction
9.2. Acromegaly
9.3. Cushing's Disease
9.4. Neuroendocrine Tumors
10. Somatostatin Analogs Market, by Route Of Administration
10.1. Introduction
10.2. Intramuscular Injection
10.3. Subcutaneous Injection
11. Somatostatin Analogs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Services
11.4. Hospitals
12. Somatostatin Analogs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Somatostatin Analogs Market, by Dosage Form
13.1. Introduction
13.2. Cartridges
13.3. Prefilled Syringes
14. Americas Somatostatin Analogs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Somatostatin Analogs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Somatostatin Analogs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Ipsen S.A.
17.3.3. Teva Pharmaceutical Industries Ltd
17.3.4. Sandoz International GmbH
17.3.5. Sun Pharmaceutical Industries Ltd
17.3.6. Viatris Inc
17.3.7. Dr. Reddy's Laboratories Ltd
17.3.8. Fresenius Kabi AG
17.3.9. Hikma Pharmaceuticals PLC
17.3.10. Accord Healthcare Ltd
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SOMATOSTATIN ANALOGS MARKET MULTI-CURRENCY
FIGURE 2. SOMATOSTATIN ANALOGS MARKET MULTI-LANGUAGE
FIGURE 3. SOMATOSTATIN ANALOGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SOMATOSTATIN ANALOGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 42. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 43. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 48. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 79. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 80. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 85. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 86. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 92. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 97. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 98. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 103. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 104. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 109. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 116. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 127. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 128. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 139. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 140. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 145. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 146. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 151. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 152. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 157. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 158. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 163. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 164. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 170. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 175. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 176. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 181. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 182. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 187. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 188. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 193. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 194. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 206. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 207. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 212. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 213. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 218. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 219. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 242. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 243. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 266. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 267. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 278. SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 279. SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Somatostatin Analogs market report include:
  • Novartis AG
  • Ipsen S.A.
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Viatris Inc
  • Dr. Reddy's Laboratories Ltd
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Accord Healthcare Ltd

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.54 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Somatostatin Analogs Market Size, Share & Trends Analysis Report by Type (Octreotide, Lanreotide, Pasireotide), Application (Acromegaly, NET), End-use (Hospitals, Clinics), and Region with Growth Forecasts, 2025-2030 - Product Image

Somatostatin Analogs Market Size, Share & Trends Analysis Report by Type (Octreotide, Lanreotide, Pasireotide), Application (Acromegaly, NET), End-use (Hospitals, Clinics), and Region with Growth Forecasts, 2025-2030

  • Report
  • 90 Pages
  • Global
From
Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 82 Pages
  • Global
From
Somatostatin Analogs - Global Strategic Business Report - Product Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Somatostatin Analogs Market Report 2025 - Product Image

Somatostatin Analogs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Somatostatin Analogs Market

Somatostatin Analogs are a class of drugs used in the treatment of oncology. They are used to inhibit the release of hormones, such as growth hormone, which can be overproduced in certain types of cancer. Somatostatin Analogs are used to treat a variety of cancers, including neuroendocrine tumors, carcinoid tumors, and pancreatic islet cell tumors. They are also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin Analogs are administered either intravenously or subcutaneously, depending on the type of cancer being treated. The Somatostatin Analogs market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of cancer, as well as the development of new and improved drugs. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use. Some of the major companies in the Somatostatin Analogs market include Novartis, Pfizer, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.